Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of May 20, 2026, KRYS trades at $296.05 with a market cap of $8.60B and a P/E ratio of 38.58. KRYS moved +3.00% today. Year to date, KRYS is +23.43%; over the trailing twelve months it is +129.62%. Its 52-week range spans $122.80 to $319.48. Analyst consensus is strong buy with an average price target of $316.00. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
KRYS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KRYS recently traded at $296.05. Market cap is $8.60B. P/E ratio is 38.58. Revenue is $417.30M.
| Metric | Value |
|---|---|
| Price | $296.05 |
| Market Cap | $8.60B |
| P/E Ratio | 38.58 |
| EPS | $7.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $319.48 |
| 52-Week Low | $122.80 |
| Volume | 170.35K |
| Avg Volume | 0 |
| Revenue (TTM) | $417.30M |
| Net Income | $225.03M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $389.13M | $204.83M | $7.08 |
| 2023 | $50.70M | $10.93M | $0.40 |
| 2022 | $0 | $-139.97M | $-5.49 |
| 2021 | $0 | $-69.57M | $-3.13 |
10 analysts cover KRYS: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $316.00.